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EDITORIAL
We Call for iCAALL: International Collaboration in
Asthma, Allergy and Immunology
Jan Lötvall, MD, PhD,1 Ruby Pawankar, MD, PhD,2 Dana V. Wallace, MD,3 Cezmi A. Akdis, MD,4
Lanny J. Rosenwasser, MD,5 Richard W. Weber, MD,6 A. Wesley Burks, MD,7 Thomas B. Casale, MD,8
Richard F. Lockey, MD,9 Nikolaos Papadopoulus, MD, PhD,10 Stanley M. Fineman, MD,11
and Dennis K. Ledford, MD,12 on behalf of the American Academy of Allergy, Asthma & Immunology
(AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI), the European Academy of
Allergy and Clinical Immunology (EAACI), and the World Allergy Organization (WAO)* Göteborg,
Sweden, Tampa and Ft. Lauderdale, Florida, Tokyo, Japan, Davos, Switzerland, Kansas City, Missouri,
Denver, Colorado, Chapel Hill, North Carolina, Omaha, Nebraska, Athens, Greece, and Atlanta, Georgia
The incidence of allergic diseases and asthma is increasingthroughout the world, and therefore these diseases pose
major medical and socioeconomic problems globally.1,2 This
is particularly true in the developed world, which has expe-
rienced a tremendous increase in the prevalence of allergic
diseases and asthma over the last 50 years.2,3,4,5 Asthma cur-
rently affects 8% to 12% of the population in the developed
world, and the prevalence of allergic rhinitis continues to
increase and currently affects approximately 20% to 25% of
this same population.6,7 Patients affected by these allergic
disease states are recognized to have a poorer quality of life,
reduced work productivity and school attendance, comorbid-
ities, and increased health care costs.2
The reasons for the negative effects of allergies and
asthma are variable, but in most countries patients with these
diseases are either inadequately or improperly treated, result-
ing in a greater negative effect and resources expended. The
awareness of these trends among politicians, other policy-
makers, patients, the general public, and many health care
insurers outside the specialty of allergy and immunology is
limited. This lack of awareness and knowledge gap has
resulted in reduced resources allocated to treat and promote
research for these diseases.
Over the past 2 decades, the population of the world has
increased from approximately 5.3 to 7 billion, and by the year
2050, it is estimated to reach 9 to 10 billion. As rapid
population growth occurs, people are more likely to live in
urban environments. In fact, some estimates predict that 60%
to 70% of the world’s population will live in cities and their
surrounding areas by 2050. Because urbanization results in
lifestyle changes and an increased exposure to environmental
pollutants, an even further increase in the prevalence of aller-
gic diseases and asthma is expected worldwide.
This is illustrated by the fact that allergic diseases and
asthma increase in parallel to urbanization.8 Some futurists
estimate that the prevalence of asthma will affect 10%, or
approximately 1 billion, of the world’s population by 2050.
This increase will not only affect the collective quality of life
of these populations but also negatively affect their econo-
mies. Likewise, several billion persons will have other
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allergic diseases, such as allergic rhinitis, with a concomitant
increased incidence of comorbidities.
To address these concerns and prepare for the resulting
needs worldwide, the American Academy of Allergy, Asthma
& Immunology; the American College of Allergy, Asthma &
Immunology; the European Academy of Allergy and Clinical
Immunology; and the World Allergy Organization have
formed a collaborative outreach program termed the Interna-
tional Collaboration in Asthma, Allergy and Immunology
(iCAALL). The mission of iCAALL will be to increase and
coordinate the communication of information about allergies,
asthma, and immunologic diseases on a global level. It will
develop communications tools for specialists, general practi-
tioners, and other health care professionals and, ultimately,
provide information for the general public, patients, and pol-
icymakers around the world. Hopefully, this consorted effort
will result in a greater awareness about allergies, asthma, and
immunologic diseases, resulting in more competent care for
patients by health care professionals and increased allocation
of resources for research and patient care, thus beneﬁtting
these patients and societies as a whole.
The ﬁrst project underway is for iCAALL to produce
international consensus statements (ICONs) to serve as
important resources for physicians and other health care
professionals who care for and manage patients with allergic
and immunologic diseases. ICONs will also serve to educate
policymakers about the need to provide access to care and
resource allocation to ensure optimal patient care. Two
ICONs on eosinophilic diseases and pediatric asthma are
currently under development, and a third on food allergy has
recently been published.9 Additional ICONs will be devel-
oped in future years. These concise documents will be auth-
ored by a multinational group of experts who will review the
pertinent literature and summarize the salient points of vari-
ous allergic diseases, including their pathogenesis, clinical
characteristics, and treatment.
iCAALL will also promote awareness, collaboration,
and international recognition of allergy, asthma, and immu-
nologic diseases. This will include the development of con-
sensus documents and possibly guidelines for the diagnosis
and treatment of various allergic and immunologic diseases
and asthma. The developmental process will involve a large
group of worldwide specialists; other health care professio-
nals, including primary care physicians; and the patients we
serve and will use both traditional and newer Internet-based
interactive techniques for sharing data and opinions. The
ICONs will combine the best scientiﬁc evidence with expert
consensus and will be adaptable for all countries worldwide,
allowing for modiﬁcations based on the availability of
regional diagnostic and therapeutic interventions. Using this
new approach, iCAALL is optimistic that it will be possible
to achieve universal acceptance of the evolving consensus
documents by the health care community, thereby helping to
create a bridge between specialists and primary care physi-
cians: the world will have a more pragmatic approach to the
diagnosis and treatment of these common diseases.
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